Sisunatovir

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.

Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.

JMP Securities' Roy Buchanan reiterates Buy rating on Enanta Pharmaceuticals (ENTA) with a $22.00 price target, citing Pfizer's discontinuation of sisunatovir and promising results from zelicapavir's pediatric trial. Buchanan also highlights EDP-323's robust impact in an RSV challenge trial, positioning Enanta favorably in the RSV therapeutic market.